Featured Articles

Time Intervals Until the First Return Office Visit After New Medications

By December 15, 2020No Comments

Featured Article

Featured Article

Making contact with patients within a week of prescribing a new medication may improve treatment adherence, suggest the authors of a recent study.

Read more

Making contact with patients within a week of prescribing a new medication may improve treatment adherence, suggest the authors of a recent study.

Heather Onorati

Making contact with patients within a week of prescribing a new medication may improve treatment adherence, suggest the authors of a recent study.

In patients with acne, atopic dermatitis and psoriasis, specifically, poor adherence to topical treatments has been a common challenge, according to studies. One reported reason is dissatisfaction with treatment efficacy. Closing the gap between prescription and follow-up visit may encourage patients to fill prescriptions sooner; initial efficacy may motivate further compliance, according to the study.

“Shortening the time to the first return visit may make doing the treatment appear to be less burdensome,” write Steven R. Feldman, M.D., Ph.D., and colleagues.

The group analyzed data representing 10.9 million estimated visits that were logged in the National Ambulatory Medical Care Survey and represented diagnoses for acne, atopic dermatitis and psoriasis between the years 2014 and 2016, which was the most recent available data. The time to a first return visit for patients with acne, atopic dermatitis and psoriasis who were prescribed at least one new medication was often more than two months regardless of whether they were prescribed a new medication.

Whether reasons for scheduling long intervals are due to tradition or unawareness of more optimal timeframes is not well known, the authors write.

Previous studies have indicated that adherence increases around the time of an office visit and then decreases rapidly in the days afterward, they note. Physicians may be able to use this tendency to create accountability for patients to begin and continue treatments.

“If a decreased interval between office visits can improve initial adherence, patients may see greater efficacy when using medications and be encouraged to continue their treatments,” the authors write.

While in-person follow-up visits may not be feasible for all patients due to travel distance, cost or other barriers, the authors note other methods of contacting and engaging the patient that have been shown to improve adherence, such as phone calls, emails, text messages and telemedicine visits.

“A lack of accountability may be an underappreciated component of non-adherence,” the authors write. “The timing of return visits may be an important factor to consider … for overcoming the adherence hurdle.”

Read Full Article Now
Heather Onorati is an experienced medical writer and editor with more than 20 years covering the dermatology industry.
Article Cited in this Post

You May Also Like

Journal of Drugs in Dermatology JDD Article About Antioxidant, Keratolytic, and Hydrating Treatment for Seborrheic Keratoses. Image from the Full Spectrum of Dermatology: A Diverse and Inclusive Atlas of a darker skin tone back or torso with a seborrheic keratoses.

Antioxidant, Keratolytic, and Hydrating Treatment for Seborrheic Keratoses

| Featured Articles, JDD Highlights, Latest News, The Latest | No Comments
JDD Spotlight: A Novel Topical Approach for Seborrheic Keratoses? Could a new topical formula change the way we manage seborrheic keratoses? In a pilot study, a unique blend of antioxidants,…

JDD in the News: Micropeptide Addresses Aging, Inflammation

| Acne, Derm Community, Featured Articles, JDD Highlights, JDD in the Media, The Latest | No Comments
A recent Journal of Drugs in Dermatology study about a micropeptide with anti-aging and anti-inflammatory effects made news in Dermatology Times. The study, “Acetyl Dipeptide-31 Amide: A Novel Cosmetic Anti-Inflammatory…
Journal of Drugs in Dermatology JDD Article About Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses. Image from the Full Spectrum of Dermatology: A Diverse and Inclusive Atlas of a darker skin tone elbow with psoriasis.

Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses

| Featured Articles, JDD Highlights, Latest News, Psoriasis, The Latest | No Comments
JDD Spotlight: Guselkumab’s 5-Year Promise in Psoriasis Curious about long-term breakthroughs in psoriasis care? A recent pooled analysis from the Phase 3 VOYAGE studies hints that guselkumab might be a…

Leave a Reply